Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Provided By GlobeNewswire
Last update: Nov 18, 2024
NORCROSS, Ga., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and portal hypertension at the American Association for the Study of Liver Diseases (AASLD)’s annual meeting 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, California.
Read more at globenewswire.com2.42
-0.87 (-26.44%)
Find more stocks in the Stock Screener
GALT Latest News and Analysis
16 hours ago - ChartmillThese stocks are moving in today's sessionKeep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
4 days ago - ChartmillThese stocks are moving in today's sessionKeep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
4 days ago - ChartmillWhich stocks are moving on Tuesday?Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
